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Abstract
Introduction Body image is acknowledged as an important aspect of health-related quality of life in cancer patients. The Body
Image Scale (BIS) is a patient-reported outcome measure (PROM) to evaluate body image in cancer patients. The aim of this
study was to systematically review measurement properties of the BIS among cancer patients.
Methods A search in Embase, MEDLINE, PsycINFO, and Web of Science was performed to identify studies that investigated
measurement properties of the BIS (Prospero ID 42017057237). Study quality was assessed (excellent, good, fair, poor), and data
were extracted and analyzed according to the COnsensus-based Standards for the selection of health Measurement INstruments
(COSMIN) methodology on structural validity, internal consistency, reliability, measurement error, hypothesis testing for con-
struct validity, and responsiveness. Evidence was categorized into sufficient, insufficient, inconsistent, or indeterminate.
Results Nine studies were included. Evidencewas sufficient for structural validity (one factor solution), internal consistency (α =
0.86–0.96), and reliability (r > 0.70); indeterminate for measurement error (information on minimal important change lacked)
and responsiveness (increasing body image disturbance in only one study); and inconsistent for hypothesis testing (conflicting
results). Quality of the evidence was moderate to low. No studies reported on cross-cultural validity.
Conclusion The BIS is a PROM with good structural validity, internal consistency, and test-retest reliability, but good quality
studies on the other measurement properties are needed to optimize evidence. It is recommended to include a wider variety of
cancer diagnoses and treatment modalities in these future studies.
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Introduction
Patients with cancer are often faced with invasive treatments,
with a temporal or permanent impact on appearance. Cancer
patients may have to deal for example with scars or amputated
body parts following surgery, skin burns due to radiation ther-
apy, or hair loss due to chemotherapy. These appearance
changes can negatively affect body image. Body image is a
multi-dimensional construct and comprises cognitive, behav-
ioral, and affective aspects of appearance [1]. For instance,
altered body appearance after cancer treatment can be accom-
panied with feelings of shame, negative self-esteem, or social
avoidance [2, 3]. For some patients, negative aspects of body
image are persistent and remain prevalent years after treatment
[4, 5] and can negatively impact quality of life. Therefore,
body image is considered to be an essential factor of health-
related quality of life (HRQOL) in cancer patients [6, 7].
Monitoring HRQOL (including body image) in clinical prac-
tice is important to identify patients who may benefit from
supportive care, and patient-reported outcome measures
(PROMs) are often used for that purpose [8, 9].
The Body Image Scale (BIS) is a PROM developed to
measure body image in all types of cancer patients. This is
in contrast to other PROMs that aim tomeasure body image in
non-cancer populations (e.g., Appearance Schemas
Inventory-Revised (ASI-R)) [10] or in cancer patients with
specific types of cancer or treatment (e.g., Breast Impact of
Treatment Scale (BITS) in breast cancer patients, Sexual
Adjustment and Body Image Scale (SABIS-g) in gynecologic
cancer patients, and Body Image Screener for Cancer
Reconstruction (BICR) for patients after breast reconstruc-
tion) [11–13]. The initial development and validation study
of the BIS showed good measurement properties concerning
internal consistency, known-group comparison and respon-
siveness among English-speaking breast cancer patients
[14]. Since then, the BIS was validated in several other lan-
guages such as Dutch, Greek, and Portuguese [15–17] and
across diverse cancer populations, e.g., in advanced cancer
patients and colorectal cancer patients [18, 19]. Recently,
Muzzatti et al. (2017) presented a review of PROMs measur-
ing body image in cancer patients, including the BIS, and
concluded that the measurement properties of these PROMs
require more thorough investigation [20]. With respect to the
BIS specifically, they concluded that the measurement prop-
erties were adequate, except for inconsistent results regarding
structural validity and lacking evidence for criterion validity.
However, not all measurement properties were taken into ac-
count (i.e., measurement error and responsiveness).Moreover,
no guideline was used to interpret results, and the methodo-
logical quality of the extracted studies was not assessed.
Therefore, the aim of this current study was to conduct a
systematic review specifically focusing on the measurement
properties of the BIS in cancer patients, following the
COnsensus-based Standards for the selection of health
Measurement INstruments (COSMIN) methodology.
The COSMIN methodology is based on taxonomy and
definitions of measurement properties for PROMs [21] in-
cluding content validity, structural validity, internal consisten-
cy, cross-cultural validity, reliability, measurement error, cri-
terion validity, hypotheses testing for construct validity, and
responsiveness. The current study will add important informa-
tion to the previous review [20], which is of high importance
when considering the use of the BIS in clinical trials and
practice as well as for interpretation of BIS outcomes.
Methods
The Body Image Scale
The 10-item Body Image Scale was developed by Hopwood
et al. in 2001 to measure affective, behavioral, and cognitive
body image symptoms. Patients can indicate body image
symptoms on a 4-point scale (0 Bnot at all^ to 3 Bvery much^).
The total score ranges from 0 to 30 and can be calculated by
summing up the 10 items. A higher score means a higher level
of body image disturbance [14].
Literature search strategy
This study was part of a larger systematic review (Prospero ID
42017057237) [22], investigating the validity of 39 PROMs
measuring quality of life of cancer survivors included in an
eHealth application called BOncokompas^ [23–25]. Before
the actual search, a search for reviews and meta-analyses of
the measurement properties of each of the 39 PROMs was
performed. This search did not yield any relevant results for
the BIS.
The databases Embase, MEDLINE, PsycINFO, and Web
of Science were systematically searched for publications di-
rectly investigating aspects of measurement properties of the
BIS. Search terms were the measurement instrument’s name
and its acronym, combined with search terms (text words and
key words) for cancer, and a precise filter for measurement
properties (Appendix A) [26]. The search was performed in
July 2016 and updated in July 2017 to verify new publica-
tions. Search results were checked for duplications.
Inclusion and exclusion criteria
Studies were included that reported on original data about at
least one measurement property as defined in the COSMIN
taxonomy [21] related to the BIS. Validation studies of other
PROMs that reported original data on the BIS (as comparison
instrument) were also included. The COSMIN taxonomy [21]
distinguishes nine measurement properties for PROMs: (1)
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structural validity (degree to which scores of a PROM are an
adequate reflection of the dimensionality of the construct to be
measured), (2) internal consistency (degree of interrelatedness
among items), (3) reliability (the extent to which scores for
patients who have not changed are the same for repeated mea-
surement under several conditions), (4) measurement error
(systematic and random error of a patient’s score that is not
attributed to true changes in the construct to be measured), (5)
hypothesis testing for construct validity (degree to which the
scores are consistent with hypotheses on known-groups com-
parison, and on relations to scores of other PROMs (convergent
and divergent validity)), (6) criterion validity (degree to which
the scores are an adequate reflection of a gold standard), (7)
responsiveness (the ability of a PROM to detect change over
time in the construct to be measured), (8) cross-cultural validity
(degree to which the performance of the items on a translated or
culturally adapted PROM are an adequate reflection of the
performance of the items of the original version), (9) content
validity (degree to which the content of a PROM is an adequate
reflection of the construct to be measured). In the present re-
view study, we did not evaluate content validity because no
protocol existed to evaluate this measurement property.
We excluded studies that were conference proceedings,
studies without full-text available, publications in other lan-
guages than English, and studies that investigated populations
without cancer. Full-text publications were reviewed by two
independent raters (KN and FJ). Disagreements regarding in-
clusion and exclusion were discussed until consensus was
reached.
Data extraction
Two independent extractors (KN and FJ) who identified eligi-
ble studies extracted information on each of the measurement
properties defined in the COSMIN taxonomy [21]. Relevant
data included the study population, sample size, the method,
information on missing values, type of measurement property,
and its outcome. Disagreements were discussed until consen-
sus was reached.
Data analyses
Data analyses were performed in three steps to accomplish
adequate interpretation of the results, following the
COSMIN methodology [27].
First, we rated the methodological quality of the included
studies, based on the COSMIN checklist for assessing the
methodological quality of studies on measurement properties
[28]. Methodological aspects regarding design requirements
and preferred statistical methods, specific to the measurement
properties under consideration were rated on a 4-point scale:
Bexcellent,^ Bgood,^ Bfair,^ or Bpoor.^ In accordance with
COSMIN recommendations, overall methodological quality
per measurement property of the BIS was obtained by taking
the lowest rating of any of the methodological aspects
assessed [29].
Second, criteria for good measurement properties were ap-
plied to the results of the included studies, following the
COSMIN guidelines for systematic reviews of PROMs [27,
30]. Each measurement property in each individual study was
rated as Bsufficient^ (+), Binsufficient^ (−), or Bindeterminate^
(?). For example, hypothesis testing for construct validity is
rated as Bsufficient^ if at least 75% of the results are in accor-
dance with the hypotheses. These results were qualitatively
summarized to obtain an overall rating of the measurement
property across all included studies: sufficient (+), insufficient
(−), Binconsistent^ (±) or indeterminate (?). If all studies indi-
cated sufficient or insufficient results, the overall rating was
accordingly. If there were inconsistencies between studies, ex-
planations were explored. If no explanations were found, the
overall rating would be inconsistent. The overall rating would
be indeterminate if not enough information was available [27].
In the third step, this overall rating of evidence was supple-
mented by a level of quality of the evidence, using a modified
Grading of Recommendations Assessment, Development and
Evaluation (GRADE) approach from the COSMIN method-
ology to grade the confidence in the total body of evidence
available for the measurement properties [27]. Quality of the
evidence was graded as high, moderate, low, or very low. This
grade was based on (i) risk of bias, (ii) indirectness, (iii) in-
consistency of results, and (iv) imprecision of studies. Each
study was rated by a single rater (HM), whose ratings were
checked by a second independent rater (KN). Discrepancies in
ratings were discussed until consensus was reached.
Results
Search results
In total, 980 non-duplicate abstracts were screened, of which
208 abstracts concerned the BIS. The 2017 search update
resulted in 16 extra abstracts on the BIS. Having applied in-
clusion and exclusion criteria, 177 studies were excluded after
title/abstract screening. Of the remaining 47 studies, 37 were
excluded after full-text screening and one was excluded dur-
ing data extraction. In total, we included nine studies that
investigated measurement properties of the BIS in cancer pa-
tients (see Fig. 1).
Study characteristics
Table 1 summarizes the characteristics of the included studies.
One study described the development and validation of the
BIS in English [14]. Six studies examined validity of the
translated BIS in other languages (Greek, Spanish, Korean,
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Portuguese, Dutch, and Turkish) [15–17, 31–33]. In one
study, screening of body image in patients with advanced
cancer (locally advanced, recurrent, or metastatic) was specif-
ically the focus [18]. One study validated the BIS in colorectal
Fig. 1. Flow diagram of the
systematic search
Table 1 Characteristics of included studies
Reference Main aim of study Population Sample
size
Anagnostopoulos
et al. [16]
Examining reliability and validity of Body Image
Scale in Greek
Breast cancer patients treated with mastectomy or
breast-conserving surgery; Greece
70
Gómez-Campelo
et al. [31]
Validation of Body Image Scale in Spanish Breast and gynecological cancer patients; Spain 100
Hopwood et al.
[14]
Development and validation of Body Image Scale
in English
Breast cancer patients; UK 682
Karayurt
et al. [32]
Validation of Body Image Scale in Turkish Ostomy patients; Turkey 100
Khang
et al. [33]
Validation of Body Image Scale in Korean Breast cancer patients treated with mastectomy,
breast-conserving surgery or oncoplastic surgery;
South Korea
155
Moreira
et al. [17]
Validation of Body Image Scale in Portuguese Postoperative breast cancer patients; Portugal 173
Rhondali
et al. [18]
To examine the construct of body image
dissatisfaction
and its measurement using a single question in
patients with advanced cancer
Advanced cancer; USA 81
Van Verschuer
et al. [15]
Validation of Body Image Scale in Dutch Breast cancer patients who have received breast conserving
treatment or mastectomy; The Netherlands
209
Whistance
et al. [19]
Validation of Body Image Scale for colorectal
patients undergoing surgery
Colorectal cancer patients undergoing surgery; UK 82
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cancer patients undergoing surgery [19]. The study popula-
tions were breast cancer patients [14, 17, 33], colorectal cancer
patients [19], patients with an ostomy (included because 82%
of the population were cancer patients) [32], or a mixed cancer
population (including breast, gynecological, gastro-intestinal,
genitourinary, head and neck, hematologic, and respiratory
cancer) [18, 31]. We report on the results based on data ex-
tracted from nine studies addressing structural validity, inter-
nal consistency, reliability, hypothesis testing for construct
validity, and responsiveness. Although none of the studies
reported on measurement error, this could be calculated for
three studies. None of the studies presented results on cross-
cultural validity or criterion validity.
Measurement properties
Structural validity
In total, seven studies examined structural validity using ex-
ploratory factor analyses (EFA) [14, 16, 17, 19, 31–33] and
three studies performed an additional confirmatory factor
analysis (CFA) [16, 31, 32] (Table 2).
Two studies of excellent [14] and good [33] quality con-
cluded that, over the total study sample, the BIS has a one-
factor solution. In subgroup analyses, a two-factor structure
was found among breast cancer patients after mastectomy [14]
and breast cancer patients after surgery with immediate breast
reconstruction [33]. Three fair quality studies also reported a
one-factor solution [17, 31, 32] and one fair quality study
reported a two-factor solution [16] among breast cancer pa-
tients after breast-conserving surgery (BCS) ormastectomy. In
the poor quality study [19], a multi-trait item analysis was
performed.
Based on these findings, structural validity of the BIS over-
all was rated sufficient (+) because two studies of at least good
quality and three studies of fair quality support unidimension-
ality of the scale. It should be noted that in some studies, a
two-factor solution was also found. The quality of evidence of
structural validity was graded as moderate due to inconsistent
findings.
Table 2 Structural validity of the BIS
Reference Methodology Results Methodological quality
Rating
Anagnostopoulos
et al. [16]
EFAa, CFAb Two factor solution: perceived attractiveness accounting
for 52.7% of the variance, and body appearance satisfaction
accounting for 8.4% of the variance. The two factors were
positively intercorrelated (r = 0.81). Fit statistics were
adequate. RMSEA: 0.058; SRMR: 0.069; CFI: 0.95.
Fair –
Gómez-Campelo
et al. [31]
EFA, CFA One factor solution accounting for 81.03% of the variance
with acceptable fit statistics. SRMR: 0.059.
Fair +
Hopwood
et al. [14]
EFA One factor solution in three analyses accounting for 50.1–57.6%
of variance. Two-factor solution for mastectomy subgroup:
appearance/attractiveness (26.9% of variance) and body
satisfaction (18.8% of variance) but results were not reproducible.
Excellent +
Karayurt
et al. [32]
EFA, CFA One-factor solution, fit statistics were acceptable. SRMR: 0.05;
CFI: 0.96.
Fair +
Khang
et al. [33]
EFA One-factor solution for global (66.6% of variance), BCS
(59.9% of variance), and mastectomy (74.4% of variance)
subgroups. Two-factor solution for oncoplastic subgroup
(40.2 and 28.6% of variance).
Good +
Moreira
et al. [17]
PCAc One-factor solution with eigenvalue of 6.12, explaining
61.2% of variance.
Fair +
Whistance
et al. [19]
Multi-trait item scaling One-factor solution single items each correlated well with the
overall ten-item BIS scale with the exception of item 10
(r = 0.39). Removal of this item improved the scaling.
Factor analysis suggested a one-factor solution, but item
10 had the lowest factor loading (0.41). This analysis
was also repeated with item 10 excluded, and the factor
loadings of the remaining nine items improved.
Poor ?
+ sufficient.? Indeterminate, − insufficient, NA not applicable, RMSEA root mean square error of approximation, SRMR standardized root-mean-square
residual, CFI comparative fit index BCS breast-conserving surgery
a Exploratory factor analysis
b Confirmatory Factor Analysis
c Principal Component Analysis
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Internal consistency
All nine included studies reported on internal consistency
using Cronbach’s alpha (α) (Table 3). In the excellent and
good quality studies, values ranged between α = 0.86–0.96
[14, 15, 19, 33]. These results are sufficient for internal con-
sistency (α ≥ 0.70 and ≤ 0.95) [27], although in one mastecto-
my subgroup, a value of α = 0.96 was presented, which might
reflect overlap of items within the scale. Five studies had fair
methodological quality since missing items were not de-
scribed. Of these studies, four showed sufficient internal con-
sistency [16–18, 32] and one [31] showed insufficient results
because of values of α = 0.97 in all subgroups.
Based on these findings, internal consistency of the BIS
overall was rated as sufficient (+) and the quality of evidence
of internal consistency was graded as moderate because there
is moderate evidence for the unidimensionality of the scale.
Reliability
Four studies examined test-retest reliability. The good and fair
quality studies reported values of r = 0.92 [15] and r = 0.85
[32], indicating sufficient results. Two studies had poor qual-
ity and therefore indeterminate results because the time inter-
val was considered too long (6 months compared to 2 weeks
in the other studies) [33] and because of a small sample size
(n = 19) [19], reporting values of ICC = 0.67 and r = 0.89,
respectively. The low value of 0.67 may be an underestima-
tion of the true reliability because of the long time interval.
Hence, reliability of the BIS overall was rated as sufficient (+).
Table 3 Internal consistency
(Cronbach’s α) of the BIS Reference (Sub)groups Value
(α)
Methodological
quality Rating
Anagnostopoulos et al.
[16]
Satisfaction subscale (7 items) 0.87 Fair +
Attractiveness subscale (3 items) 0.92
General body image concerns (5
items)
0.81
Gómez-Campelo et al.
[31]
Total sample 0.97 Fair –
Breast cancer subgroup 0.97
Gynecological cancer subgroup 0.97
Hopwood et al.
[14]
Total sample 0.93 Excellent +
BCS subgroup 0.91
Mastectomy subgroup 0.91
Remaining subgroupsa 0.86
Karayurt et al.
[32]
Total sample 0.94 Fair +
Khang et al.
[33]
Total sample 0.94 Good +
BCS subgroup 0.92
Mastectomy subgroup 0.96
Oncoplastic surgery subgroup 0.92
Moreira et al.
[17]
Total sample 0.93 Fair +
BCS subgroup 0.93
Mastectomy subgroup 0.92
Rhondali et al.
[18]
Total sample 0.88 Fair +
Van Verschuer et al.
[15]
Total sample (time 1) 0.91 Good +
Total sample (time 2) 0.92
Whistance et al.
[19]
Total sample (9-item scale) 0.90 Good +
BCS breast-conserving surgery
a Breast cancer patients, advanced breast cancer patients, breast cancer patients with oncoplastic surgery, genetic
high-risk women following bilateral prophylactic mastectomy
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The quality of evidence of reliability was graded as moderate
because three out of four studies reported Pearson/Spearman’s
correlation coefficients [15, 32, 33], while an intraclass corre-
lation coefficient (ICC) would have been more appropriate.
Measurement error
Although measurement error was not reported in the included
studies, we were able to calculate the standard error of mea-
surement (SEM) and the smallest detectable change (SDC) in
three studies reporting reliability data and standard deviations.
Two studies of good [15] and fair quality (n = 40) [32] had an
SDC of 4.7 (SEM= 1.7) and 9.1 (SEM= 3.3), respectively.
The poor quality study because of the large time interval be-
tween the measurements had an SDC of 11.1 (SEM = 4.0)
[33]. Interpretation of measurement error is only possible if
a SDC score is compared with data on minimal important
change (MIC), but this was not reported. Based on these find-
ings, measurement error of the BIS overall was graded as
indeterminate (?).
Hypothesis testing for construct validity
Known-groups comparison Eight studies performed known-
group comparisons (Table 4). No a priori hypotheses were
formulated in four studies [15, 17, 18, 33], and in those cases,
we assumed the hypothesis would be that BIS scores are
higher (worse) (1) in patients who were treated with a mastec-
tomy compared to patients treated with BCS [34] or breast
reconstruction [35], (2) in younger patients compared to older
patients [36], (3) in patients with a longer time since treatment
[37], and (4) in patients with a stoma vs. without a stoma [38].
Two studies with good quality confirmed their hypotheses
[14, 19]. Out of five studies with fair quality [15–17, 31,
33], two studies confirmed the hypotheses [15, 16]. One study
had a poor quality [18] because no a priori hypotheses were
formulated.
Convergent and divergent validity Six studies reported on
convergent validity with other body image-related instru-
ments, psychological function, or HRQOL scales (Table 4).
One good quality study [19] showed moderate correlation
(r = 0.40 to 0.60) with a related construct but failed to confirm
their hypotheses on three other constructs, indicating insuffi-
cient convergent validity. One study of fair quality [31] found
moderate and high correlations (r > 0.60) with related con-
structs, indicating sufficient convergent validity. However,
three other fair quality studies [16, 17, 33] presented low cor-
relations (r < 0.40) with most of the related constructs, indi-
cating insufficient convergent validity. The poor quality study
did not formulate a hypothesis a priori [18]. None of the stud-
ies in this review examined divergent validity.
Based on these findings, hypothesis testing for construct
validity was rated as inconsistent (±) because although three
studies showed sufficient evidence (> 75% of the hypotheses
on known-groups and/or convergent validity confirmed) [14,
15, 31], this was contradicted by four studies showing insuf-
ficient evidence [16, 17, 19, 33]. Moreover, studies reported
inconsistent results in comparison with the same instrument
(ASI-R and RSES) [17, 18, 33]. For this reason, and due to the
lack of clearly stated a priori hypotheses, quality of evidence
of construct validity was graded as low.
Responsiveness
Two studies reported on responsiveness. One study of good
quality [14] found a significant increase in body image distur-
bance for the overall sample (n = 55) and for the BCS and
mastectomy subgroups 2 weeks to 4 months postoperatively,
indicating sufficient responsiveness. The other study had poor
quality [19] because of a small sample size (n = 17) and found
no change in BIS scores from before to after surgical treat-
ment. Based on these findings, responsiveness of the BIS was
rated as indeterminate (?). An overall summary of the results
for every measurement property of the BIS is shown in
Table 5.
Discussion
This systematic review evaluated the measurement properties
of the BIS among nine studies identified in a literature search
up to July 2017. In summary, evidence on structural validity,
internal consistency, and reliability of the BIS was rated as
sufficient, and the quality of evidence was moderate.
Measurement error and responsiveness were rated as indeter-
minate, and hypothesis testing for construct validity was rated
as inconsistent with a low quality of evidence. None of the
studies reported on criterion validity and cross-cultural
validity.
For structural validity, a one-factor solution was found and
evidence was rated as sufficient. However, one fair quality
study and subgroup analyses in two good quality studies
showed a two-factor structure [14, 16, 33]. Hopwood et al.
[14] found a two-factor structure among breast cancer patients
after mastectomy, and Khang et al. [33] after surgery with
immediate breast reconstruction. These two factors were la-
beled as Battractiveness^ and Bsatisfaction with body^ [14,
16]. However, there was no agreement on which items
belonged to which factors precisely. Also, the findings were
inconsistent and in the study of Khang et al. [33] based on a
relatively small study sample (subgroup n < 50). Further re-
search is therefore needed to investigate whether the BIS is a
unidimensional construct in all breast cancer patients, regard-
less of treatment modality.
Support Care Cancer (2018) 26:1715–1726 1721
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Evidence on reliability was sufficient because it met the
criterion of 0.70 in three out of four studies (range 0.67–
0.92). The one study that found a correlation < 0.70 had a
large time interval (6 months) between the two measurements
and was therefore judged as having a poor methodological
quality. It is known that body image symptoms can change
in the first few months after cancer treatment [14], with pa-
tients reporting high deterioration and recovery trajectories
[39]. Moreover, body changes (e.g., weight fluctuations or
healing of wounds) can occur within half a year. A 7–14-day
interval for test-retest reliability is in general considered most
appropriate [30].
Measurement errorwas not reported in any of the included
studies, but the SDC could be calculated in three studies.
When only taking into account good and fair quality studies,
the smallest change in score that can be detected, that is not
due tomeasurement error, ranges between 4.7–9.1 [15, 32], on
a total range of 0–30 of the BIS. However, these data are
difficult to interpret since no information is available on the
anchor points minimal important change (MIC) or minimal
important difference (MID). Therefore, further research is
needed to establish these anchor points on changes that are
important.
Evidence on hypothesis testing for construct validity was
inconsistent since findings for known-group comparisons and
convergent validity were inconsistent. Known-group compar-
isons in most studies focused on body image issues related to
surgical treatment (comparing breast cancer patients treated
with mastectomy versus BCS). It is known that other types
of treatment may also impact body appearance. For example,
cancer survivors who received chemotherapy reported that
hair loss and weight gain disrupted their body image [40,
41]. In addition to recommendations to include other cancer
populations than breast cancer patients [20], we also recom-
mend to study construct validity of the BIS taking into account
the impact of various cancer treatments on body image.
With respect to convergent validity, correlations with other
body image scales were inconsistent. There were indications
that consciousness of appearance (DAS24) and shame (ESS)
are related with body image, with moderate to high correla-
tions [17]. However, correlation with investment in
appearance (ASI-R) was low [17, 18]. Moreover, the relation
with self-esteem (RSES) was inconsistent, with only one of
two studies finding a high correlation [31, 33]. Given these
contradictory findings and the fair quality of these studies, no
firm conclusions can be drawn about convergent validity of
the BIS. This contradicts the conclusion of Muzzatti et al.
presenting adequate convergent validity [20].
Evidence for responsiveness was indeterminate. Only one
study of good methodological quality reported a change in
BIS scores postoperatively [14], but no hypotheses were for-
mulated on the expected magnitude of change and no com-
parison with another instrument was made. More research is
needed about the ability of the BIS to detect change in body
image symptoms over time.
A limitation of this review is that content validity was not
investigated because at the time we conducted our data extrac-
tion, no protocol existed to investigate content validity
through a systematic review. Recently, this protocol has be-
come available [42]. Another limitation is that a precise filter
instead of a sensitive filter was used. The precise filter was a
pragmatic choice because a sensitive filter would provide too
many hits to feasibly screen since the overall search
encompassed 39 PROMs (Prospero ID 42017057237) [22].
There is a small possibility that validation studies of the BIS
may have been missed. Lastly, the assessment of quality rat-
ings was performed by one rater. This rating was then checked
by a second independent rater, and discussed until consensus
was reached. The gold standard practice is to have the assess-
ment done by two raters independently because raters initially
may have different opinions and consensus is needed.
This systematic review provides in-depth insight of the
current evidence of the BIS as an instrument to measure body
image in cancer patients and complements a recent review
[20]. For researchers who want to further study the psycho-
metric properties of the BIS, this paper points out future di-
rections. With respect to reliability, this includes examining
measurement error and research on minimal important
change. Regarding validity, existing evidence on content va-
lidity should be summarized and new evidence is needed for
cross-cultural validity. Criterion validity is impossible to as-
sess, since a Bgold standard^ for assessing body image is not
Table 5 Overall rating of the
results and levels of evidence of
the BIS
Measurement property Rating of measurement property Quality of evidence
Structural validity + Moderate
Internal consistency + Moderate
Reliability + Moderate
Measurement error ?
Hypothesis testing ± Low
Cross-cultural validity NA NA
Criterion validity NA NA
Responsiveness ?
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available. Efforts are therefore needed to reach consensus on a
measure that could serve as second best. This may comprise
body image scores by proxies such as health care providers
with vast experience in the targeted study population.
Furthermore, it would be valuable to examine structural valid-
ity on a possible two-factor structure among cancer subgroups
(patients who had reconstructive surgery or amputation of a
body part) more thoroughly. High-quality studies exploring
convergent validity with investment in appearance (ASI-R)
and self-esteem (RSES) are recommended. Finally, respon-
siveness should be more thoroughly investigated by formulat-
ing hypotheses for change scores in the BIS compared to
change scores in other instruments. The BIS is mainly tested
in a population of patients who are surgically treated for breast
cancer. Further research including a wider variety of cancer
patients and treatment modalities is recommended. New val-
idation studies with a good methodological quality can further
optimize evidence regarding the measurement properties of
the BIS.
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